Healthcare investing is best left to the experts, not venture capitalists focused on disruptive consumer technologies, write peHUB guest columnists Dr. Bijan Salehizadeh and Ryan M. Schwarz of NaviMed Capital.
4 min read · 22 October 2013
Bijan Salehizadeh of NaviMed Capital ran the numbers and found that returns from seed stage deals "aren't good enough to justify the amount of exuberance and valuation growth that we are seeing in the seed market, particularly in IT, Internet and software."
4 min read · 26 March 2012
